Back to results
US 12,268,786 B2Granted
Methods of improving the solubility and bioavailability of therapeutic agents
AssigneeMAA Laboratories, Inc.
InventorAnjani Kumar Jha
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.
Claims13
A continuous process, comprising:
- i) milling a pharmaceutical composition in a ball milling apparatus to produce a milled nanoparticle form of the pharmaceutical composition;
- wherein the milling is performed in the absence of a solvent component;
- and
- ii) coating the milled nanoparticle form of the pharmaceutical composition with one or more polymers to yield a coated nanoparticle pharmaceutical composition comprising about 10% w/w to about 12% w/w polymer, wherein the coating is performed using a melt extrusion process, a melt blown process, a spunbond process, or a high temperature milling process;
- wherein the pharmaceutical composition comprises a therapeutic agent selected from dasatinib, abiraterone, raloxifene, capecitabine, methotrexate, diclofenac, and prednisone, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
2 more elements
A continuous process, consisting of:
- i) milling a pharmaceutical composition in a ball milling apparatus to produce a milled nanoparticle form of the pharmaceutical composition;
- wherein the milling is performed in the absence of a solvent component;
- and
- ii) coating the milled nanoparticle form of the pharmaceutical composition with one or more polymers to yield a coated nanoparticle pharmaceutical composition comprising about 10% w/w to about 12% w/w polymer, wherein the coating is performed using a melt extrusion process, a melt blown process, a spunbond process, or a high temperature milling process;
- wherein the pharmaceutical composition comprises a therapeutic agent selected from dasatinib, abiraterone, raloxifene, capecitabine, methotrexate, diclofenac, and prednisone, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
2 more elements
Dependencies are inferred from the claim text.